Jennifer Papoutsis

Jan 18, 2024 | adc.bmj.com | Michele A O'Connell |Elisabeth A Northam |Amy Brown |Jennifer Papoutsis

AbstractAims Improved behaviour, mood, cognition and HbA1c have been reported with short-term use of continuous subcutaneous insulin infusion (CSII) in youth with type 1 diabetes (T1D). We sought to re-examine these findings in a randomised controlled trial (RCT), with longitudinal follow-up. Methods RCT of youth aged 7–15 years with T1D, at two tertiary paediatric centres. Participants were randomised to commence CSII or continue multiple daily injections (MDI).